OPK: Opko Health, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
0 open-market buys totaling - and 0 sales totaling - in the last 180 days.
Institutional ownership (Q2 2026)
223 institutions reported holding $302.75M of Opko Health, Inc. on Form 13F (236 the quarter before). 21 opened a new position and 31 sold out. Shares held by institutions: +1%.
| Largest holders | Shares | Value |
|---|---|---|
| Rubric Capital Management LP | 47,791,243 | $71.69M |
| BlackRock, Inc. | 36,978,893 | $55.47M |
| VANGUARD CAPITAL MANAGEMENT LLC | 14,968,930 | $22.45M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 14,934,924 | $22.40M |
| GEODE CAPITAL MANAGEMENT, LLC | 11,581,027 | $17.38M |
| STATE STREET CORP | 10,309,070 | $15.46M |
| GOLDMAN SACHS GROUP INC | 7,035,492 | $10.55M |
| UBS Group AG | 5,006,284 | $7.51M |
| Whitefort Capital Management, LP | 4,511,412 | $6.77M |
| NORTHERN TRUST CORP | 3,756,163 | $5.63M |
Clinical trial readouts
1 Phase 2 or 3 trials by Opko Health, Inc. with a primary completion date in the last 90 days or the next 12 months and no results posted yet, from ClinicalTrials.gov. (est.) = company estimate.
| Primary completion | Drug | Condition | Phase | Patients | Status | Trial |
|---|---|---|---|---|---|---|
| 2027-10 (est.) | CTAP101 | CKD Stage 3 | Phase 2 | 40 | Recruiting | NCT07494045 |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.